益方生物 (688382)

InventisBio Co., Ltd.

KSH

Tags

New QFII HoldingsQFII Heavy PositionsSSE 580 IndexPension FundsInnovative DrugsPharmaceutical ManufacturingPharmaceuticals and HealthcareFund Reduction PositionsBiological ProductsSTAR Market 200 IndexSTAR Market Biotechnology IndexTechnology Growth LayerMargin Trading and Securities Lending

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 57834.85
  • Circulating A-Shares(W): 41763.33
  • Earnings Per Share(RMB): -0.31
  • Net Assets Per Share(RMB): 2.88
  • Operating Revenue(W RMB): 3089.35
  • Total Profit(W RMB): -18124.60
  • **Net Profit Attributable to Parent(W RMB) **: -18138.52
  • Net Profit Growth Rate(%): 40.59
  • Weighted Return on Equity(%): -10.42
  • Operating Cash Flow Per Share(RMB): -0.28
  • Undistributed Profit Per Share(RMB): -4.71
  • Capital Reserve Per Share(RMB): 6.62

2. Main Business

The main business covers:

  • Research and development of innovative drugs
  • Production of innovative drugs
  • Sales of innovative drugs

3. Company Basic Information

  • Company Name: InventisBio (Shanghai) Co., Ltd.
  • Listing Date: 2022-07-25
  • Industry: Pharmaceutical Manufacturing
  • Address: Room 210, No. 4, Lane 67, Libing Road, China (Shanghai) Pilot Free Trade Zone
  • Website: https://www.inventisbio.com/
  • Company Profile: InventisBio (Shanghai) Co., Ltd. was established in 2020 through the overall change of Inventis Limited. It is a biotechnology company focused on the research and development of innovative drugs. The company's unified social credit code is 913101150609007219.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Hong Kong Securities Clearing Company Ltd. Northbound Capital 1621.61 3.88
2 ABA-Bio (Hong Kong) Limited General Legal Person 1112.00 2.66
3 China Universal Innovative Medicine Theme Hybrid Securities Investment Fund Class A Fund 1031.11 2.47
4 LAV Apex Hong Kong Limited General Legal Person 897.92 2.15
5 OAP III (HK) Limited General Legal Person 837.81 2.01
6 China Europe Healthcare Hybrid Securities Investment Fund Class A Fund 814.77 1.95
7 Yongying Pharmaceutical Innovation Smart Selection Hybrid Initiation Securities Investment Fund Class A Fund 792.19 1.90
8 Shanghai Yixi Enterprise Management Center (Limited Partnership) General Legal Person 682.12 1.63
9 UBS AG QFII 629.97 1.51
10 Ping An Healthcare Hybrid Securities Investment Fund Class A Fund 627.49 1.50

5. Concept Sectors

  • Innovative Drugs
  • Margin Trading & Securities Lending
  • QFII Heavy Positions
  • Consecutive Losses
  • Pension Funds
  • QFII New Entries
  • Fund Reduction
  • Science and Technology Innovation Board Growth Layer
  • Science and Technology Innovation Board Biotech
  • Science and Technology Innovation Board 200
  • SSE 580

Remarks

  • Data update date: 2025-09-30
  • Data source: Public market information